Fact CheckerSign in

NCT05818865Active, not recruiting

"Principle Test" for Isolation and Characterization of Circulating Cancer Cells (CTC)-CXCR4+.

"Principle Test" for Isolation and Characterization of Cancer Cells (CTC)-CXCR4+ Circulating in Belotero Loaded With CXCL12 in Patients With Solid Neoplasms (Endometrium, Kidney, Glioblastoma, Colorectal, Ovary and Lung).

Source: ClinicalTrials.gov · Last updated 29 Jul 2025

Brief summary (registry, in English)

This is multicentric, interventional, non farmacological and prospective study.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
47 (estimated)
First submitted
22 Mar 2023
Start date
18 Jan 2021
Primary completion date
22 Mar 2022
Lead sponsor
National Cancer Institute, Naples
NCT number
NCT05818865

What you commit to

  • Study type: Interventional
  • Planned participants: 47
  • From 18 Jan 2021 to the primary completion date, 22 Mar 2022
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Age

  • Age \<18

Other

  • Refusal to sign informed consent

Who the study is looking for

  • Age ≥18
  • Signature of Informed Consent
  • Advanced solid neoplasm with metastases

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Istituto Nazionale Tumori - Fondazione "G.Pascale", IRCCS
Coordinator of this site? Confirm its status		NaplesItalyUnknown status
Istitute Nazionale Tumori - Fondazione G. Pascale
Coordinator of this site? Confirm its status		NaplesItalyUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.